Nebula Genomics Blockchain DNA Privacy
Sector: Quaternary sector · Industry: Biotechnology and genetic research · Organisation: Nebula Genomics · Maturity level: Concept
Nebula Genomics, co-founded by Harvard geneticist George Church, uses blockchain technology for privacy-preserving genome sequencing. Users gain full control over their DNA data through smart contracts. Researchers can run analyses on encrypted data without ever seeing the raw data. EMD Serono piloted the platform for drug development data acquisition.
Documentation status
- Project status: Concept
- Evidence: Evidence high
- Editorial review: Ufuk Avci, 15 April 2026
Description
Nebula Genomics was co-founded in 2018 by Harvard geneticist George Church. The platform combines whole genome sequencing with blockchain-based data sovereignty. Users receive inalienable ownership rights to their genome data via a public ledger. Access rights are controlled via smart contracts. Compute-to-Data enables analysis on encrypted data. EMD Serono (Merck) piloted the platform. Publications in Nature Biotechnology and Blockchain in Healthcare Today.
Nebula Genomics addresses the fundamental problem of genomics: 23andMe and Ancestry monetise their customers' DNA data — Nebula reverses the model and returns control to the users.
Perspectives
B2B — organisations perspective
Pharmaceutical companies can acquire genomic datasets for drug development without ever seeing the raw data. Compute-to-Data ensures privacy with full analysis performance.
B2C — consumers perspective
Users receive whole genome sequencing from $299 with full data control. Anonymous sequencing without identity disclosure is possible.
Employees perspective
Researchers use the platform for GWAS studies on encrypted cohorts without GDPR conflicts.
Benefits
General
- Inalienable ownership rights to genome data documented via public ledger.
- Compute-to-Data enables analysis on encrypted data without exfiltration.
- Whole genome sequencing from $299 with full data control.
B2B — organisations
- Pharmaceutical companies acquire genomic datasets for drug development without raw data access — GDPR compliant.
- Compute-to-Data significantly lowers legal barriers for genomic research.
B2C — consumers
- Users receive whole genome sequencing with full data sovereignty.
- Anonymous sequencing without identity disclosure is possible.
Employees
- Researchers conduct GWAS studies on encrypted cohorts without GDPR conflicts.
Challenges
General
- The acquisition by ProPhase Labs (2021, approx. $14.6 million) changed strategic priorities — the blockchain aspect is under further development.
- Regulatory frameworks for blockchain-based genomic data are not yet established.
B2B — organisations
- Integration of Compute-to-Data into existing pharmaceutical research pipelines requires technical adjustments.
B2C — consumers
- Users must understand and manage wallet infrastructure — a technical hurdle for non-technical target groups.
Employees
- Bioinformaticians require training in privacy-preserving computation methods.
Technology foundation
Blockchain ledger for ownership rights, Oasis Labs Secure Enclaves, homomorphic encryption, Compute-to-Data framework.
Implementation examples
Nebula Genomics / ProPhase Labs
23andMe and Ancestry monetise customer DNA without fair remuneration. Nebula reverses the model — users control and monetise their own data.
Nebula Genomics combines whole genome sequencing with blockchain-based data sovereignty — co-founded by Harvard geneticist George Church.
Nebula Genomics was co-founded in 2018 by George Church (Harvard). The platform records ownership rights to genomic data via a public ledger and controls access rights through Smart Contracts. Compute-to-Data enables analysis on encrypted data. EMD Serono (Merck) piloted the platform. In 2021, it was acquired by ProPhase Labs for approx. $14.6 million.
Data sovereignty through inalienable ownership rights. Privacy-preserving analysis without raw data exfiltration.
Tags
Genomics, Data sovereignty, Compute-to-Data, Precision medicine, Blockchain identity